Pediatric Cancer
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.
Children's Hospitals Brace for Reduced Test Access, Higher Costs Under LDT Final Rule
Pathology directors expect that they will be unable to send out or receive samples for new tests when the FDA's new LDT rule takes effect.
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
Children's Hospital LA Researcher Wins $2.8M NIH Grant for Retinoblastoma Liquid Biopsy Study
The international study will sample the aqueous humor found in children's eyes and follow participants for at least two years to monitor for cancer recurrence.